8,823,530 Shares RELMADA THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • December 13th, 2021 • Relmada Therapeutics, Inc. • Pharmaceutical preparations • New York
Introductory. Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 8,823,530 shares of its common stock, par value $0.001 per share (the “Shares”). The 8,823,530 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,323,529 Shares as provided in Section 2. The additional 1,323,529 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Goldman Sachs & Co. LLC (“Goldman”), and Jefferies LLC (“Jefferies”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To t
